YARROW BIOSCIENCE INC
YARWNASDAQTrading Snapshot
- Day Range
- $23.79 – $24.35
- 52-Week Range
- $16.00 – $46.95
- Volume
- $3.20B
- Avg Volume
- $2.90B
- Shares Outstanding
- 17,196
- Next Earnings
- Nov 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $570,000
- Last Q Revenue
- $97,000
- P/E Ratio
- -1.0
- P/S Ratio
- 0.9x
- EPS (TTM)
- $-21.81
- Dividend Yield
- 82.68%
- Dilution (1yr)
- −21.8%
Why Investors Own YARW
- ✓High-growth profile — revenue up +37.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 51% gross margin and 18% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
YARROW BIOSCIENCE INC
YARW
StockOtter · stockotter.spaceAbout YARROW BIOSCIENCE INC
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Contrasting Yarrow Bioscience (NASDAQ:YARW) and Atara Biotherapeutics (NASDAQ:ATRA)
Yarrow Bioscience (NASDAQ: YARW - Get Free Report) and Atara Biotherapeutics (NASDAQ: ATRA - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two busines
Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering
NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases
Yarrow Bioscience Announces Proposed Underwritten Public Offering
NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update
NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience reports second quarter 2026 financial results and provides a business update.
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves' Disease and Thyroid Eye Disease
NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases